Proliferative Diabetic Retinopathy

WAIKOLOA, Hawaii — Katherine E. Talcott, MD, gave an overview on managing vitreous hemorrhage in proliferative diabetic retinopathy at Retina 2022.

The results of the 2020 Global Trends in Retina Survey reveal a world that is more interconnected and where interactions between groups and individuals in the ophthalmology community increasingly grow across global borders.

In this video from the virtual American Society of Retina Specialists meeting, Jeremiah Brown Jr., MD, MS, discusses his research using the IRIS Registry to see the real-world treatments of proliferative diabetic retinopathy.

The protocol that has affected the way I practice the most is Protocol T. Protocol T was a three-arm, head-to-head study comparing the efficacy of aflibercept, ranibizumab and bevacizumab for center-involving diabetic macular edema (CI-DME) and decreased best corrected visual acuity, with these anti-VEGF drugs delivered in an individualized as-needed fashion over a 2-year time frame. This was the first study that showed any clinically meaningful differences in efficacy between the available anti-VEGF drugs for any indication, and to date, such significant differences have only been demonstrated for DME.

As a so-called expert witness, my analysis of more than 400 cases over the past 4.5 decades reveals that most cases could have been avoided if the malpractice merely covered the bases.